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http://dx.doi.org/10.1016/j.ccell.2015.08.004SUMMARYImmune checkpoint blockade of the programmed cell death protein 1 (PD-1) pathway by monoclonal anti-
bodies (Abs) has shown promising clinical benefit in the treatment of multiple cancer types. We elucidated
the contribution of the fragment crystallizable (Fc) domains of anti-PD-1 and anti-PD-ligand 1 (L1) Abs for
their optimal anti-tumor activity. We revealed that distinct Fcg receptor (FcgRs) dependency and mecha-
nisms account for the in vivo activity of anti-PD-1 versus anti-PD-L1 Abs. Anti-PD-1 Abs were found to be
FcgR independent in vivo; the presence of FcgR-binding capacity compromises their anti-tumor activity.
In contrast, the anti-PD-L1 Abs show augmented anti-tumor activity when activating FcgR binding is intro-
duced into the molecules, altering myeloid subsets within the tumor microenvironment.INTRODUCTION
The programmed cell death protein 1 (PD-1)/PD-ligand 1 (L1)
axis has a central role in the suppression of anti-tumor immunity
and has been actively studied as a potential therapeutic target
in cancer immunotherapy (Page et al., 2014). The immune
checkpoint receptor PD-1 is expressed mainly on activated lym-
phocytes (Nishimura et al., 1999) and is widely upregulated by
tumor-infiltrated T lymphocytes (TILs) (Ahmadzadeh et al.,
2009; Chapon et al., 2011). Many tumor types exploit the
PD-1 pathway to escape immune surveillance by upregulating
the expression of PD-L1 (Dong et al., 2002; Konishi et al.,
2004). Enhanced anti-tumor immunity is obtained by antibody
(Ab)-mediated blockade of the PD-1/PD-L1 axis. The therapeu-
tic potential of both anti-PD-1 and -PD-L1 Abs were demon-
strated in multiple mouse models of cancer (Blank et al.,
2004; Dong et al., 2002; Iwai et al., 2002) and in human clinical
trials (Brahmer et al., 2012; Hamid et al., 2013; Topalian et al.,
2012, 2014; Wolchok et al., 2013). Recently, the anti-PD-1
Abs pembrolizumab and nivolumab were approved by the US
Food and Drug Administration (FDA) for the treatment of meta-
static melanoma and non-small cell lung carcinoma, whereasSignificance
Therapeutic Abs targeting the PD-1/PD-L1 immune checkpoin
advanced melanoma and are currently being evaluated for th
contribution of the Fc domain to the activity of these Abs has
used for anti-PD1/PD-L1 Abs under clinical development, a de
may contribute to their therapeutic efficacy is necessary. Here
requirements for FcgR engagement for optimal anti-tumor ac
these immunomodulatory Abs for optimal clinical efficacy.
Canother antibodies targeting this pathway are in advanced stages
of clinical development.
The interaction of the Fc portion of many therapeutic anti-
tumor immunoglobulin Gs (IgGs) with Fcg receptors has been
found to be crucial for their therapeutic activities, resulting
from the induction of tumor cytotoxicity (Clynes et al., 2000).
These activities are induced through Ab-dependent cellular
cytotoxicity (ADCC) by Ttpe I FcgR-expressing effector cells,
such as natural killer cells and macrophages (Musolino et al.,
2008; Nimmerjahn and Ravetch, 2012). There are two classes
of type I FcgRs that can be distinguished functionally: the acti-
vating receptors (FcgRI, FcgRIII, and FcgRIV in mice; FcgRIA,
FcgRIIA, and FcgRIIIA in humans) and the inhibitory receptor
(FcgRIIB in both mice and humans). Effector responses medi-
ated by different IgG subclasses are dependent on their dif-
ferential affinities for activating or inhibitory FcgRs. A ratio of
activating-to-inhibitory receptor binding (A/I) can therefore pre-
dict the in vivo cytotoxic activity of IgGs (Nimmerjahn and Rav-
etch, 2005). Optimizing the effector function induced by the Fc
portion of therapeutic IgGs by increasing their A/I ratio has, as
a consequence, resulted in enhanced therapeutic responses
(Goede et al., 2014; Mo¨ssner et al., 2010).t pathway are drugs recently approved as monotherapies for
e treatment of various human malignancies. However, the
not been critically evaluated. Because Fc variants are being
tailed understanding of Fc-mediated effector activities that
we report that antibodies to PD-1 and PD-L1 have different
tivity. This study provides a rationale for Fc engineering of
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Figure 1. Distinct In Vivo Anti-tumor Activ-
ities of Chimeric Anti-PD-1/PD-L1 Anti-
bodies
(A) Mice with established MC38 tumors were
treatedwith the indicated chimeric versions of anti-
PD-L1 clone 14D8 or mIgG1 isotype control. Data
are represented as mean ± SEM (n = 10). One of
two independent experiments is shown.
(B) Mice were inoculated with B16 tumors and
vaccinated 3 days later with GVAX alone or in
combination with the indicated chimeric versions
of anti-PD-L1 clone 14D8 or mIgG1 isotype con-
trol. Data are represented as mean ± SEM (n = 6).
One of two independent experiments is shown.
(C and D) Mice with established MC38 tumors
were treated with the indicated chimeric versions
of anti-PD-1 clones 4H2 (C, n = 7), or RMP1-14
(D, n = 10), and mIgG1 isotype control. Data are
represented as mean ± SEM. One of at least two
independent experiments is shown.
See also Figure S1.In contrast to the cytotoxic class of anti-tumor Abs described
above, immunomodulatory Abs targeting molecules expressed
by immune cells have emerged as a promising approach to
induce therapeutic anti-tumor response. Immunomodulatory
Abs can act as either agonists to stimulate anti-tumor immune
responses or antagonists to dampen regulatory mechanisms
(generally referred to as immune checkpoint blocking Abs; Par-
doll, 2012). Initially, these classes of immunomodulatory Abs
were designed with the target antigen in mind, with emphasis
placed on identifying ideal fragment antigen-binding (Fab) re-
gions of Abs to engage the target appropriately. However,
recent findings highlight the importance of Fc-FcgR interactions
for the in vivo activities mediated by immunomodulatory Abs.
Antagonistic anti-CTLA-4 Abs have been shown to mediate their
in vivo effects, in part, by interacting with activating FcgRs to
deplete regulatory T cells (Treg) in the tumor microenvironment
(TME) (Bulliard et al., 2013; Selby et al., 2013; Simpson et al.,
2013). Preferential depletion of regulatory (Treg) over effector
T (Teff) cells in the TME is mainly achieved as a result of the
high surface expression of CTLA-4 on Tregs and the presence
of effector myeloid-expressing, activating FcgRs in the TME.
This FcgR-dependent mechanism was also reported for Abs
targeting immune receptors overexpressed by intratumoral
Tregs, such as GITR and OX40 (Bulliard et al., 2013, 2014). In
addition to the ADCC activity mediated by immunomodulatory
Abs, we and others have described additional pathways by
which FcgRs augment the therapeutic activities of anti-tumor
Abs. We identified a general requirement for the engagement
of the inhibitory FcgR, FcgRIIB, for the in vivo activity of
agonistic anti-TNFR Abs, such as anti-CD40, anti-DR5, and
anti-CD30 (Li and Ravetch, 2011, 2012a, 2012b, 2013). FcgRIIB
functions in trans and in the absence of FcgRIIB signaling com-
ponents, acting as a scaffold to enhance the clustering of TNFR
molecules on the membrane thereby mimicking the effect of
their endogenous multimeric ligands engaging these multimeric
receptors.286 Cancer Cell 28, 285–295, September 14, 2015 ª2015 Elsevier InIn this study, we investigate the role of Fc-FcgR interactions
for the immunomodulatory Abs targeting the PD-1/PD-L1
pathway for their therapeutic anti-tumor activities.
RESULTS
FcgREngagement by Anti-PD-1 or -PD-L1 AbsResults in
Distinct Anti-tumor Responses In Vivo
To determine the contribution of Fc-FcgR interactions to the
in vivo anti-tumor activities mediated by rat anti-mouse anti-
PD-1 and anti-PD-L1 Abs, we modified existing rat Ab clones
to create chimeric antibodies containing rat Fab and mouse Fc
domains. The mouse Fc domains were selected to vary their se-
lective engagement of mouse FcgRs, with IgG2a binding prefer-
entially to the activating Fc receptors (activating-to-inhibitory
FcgR binding [A/I] = 69), mouse IgG1 binding preferentially to
the inhibitory FcgRIIB (A/I = 0.1) and a null variant the IgG1-
D265A Fc that lacks detectable FcgR binding (Nimmerjahn and
Ravetch, 2005). We verified that the different Fc domains intro-
duced into the chimeric PD-1/PD-L1 targeting Abs did not alter
either the binding specificity or the affinity of their variable
domains to PD-L1 (clone 14D8) and PD-1 (clones 4H2 and
RMP1-14) (Figure S1A), nor their pharmacokinetic (PK) proper-
ties (Figure S1B). While there are no changes in the PK and
antigen-binding properties between the different subclasses of
each Ab clone, their differential capacity to engage mouse
FcgRs provides a means to explore the contributions of FcgR
engagement to their in vivo activity.
We compared the anti-tumor activity of the different sub-
classes of chimeric anti-PD-L1 Ab (clone 14D8) administered
as a monotherapy to mice bearing MC38 colon adenocarci-
nomas. Anti-PD-L1 Ab exhibited significant reduction in tumor
volume only when administered as IgG2a isotype (Figure 1A).
The respective isotype controls were found to have no effect
on tumor growth, eliminating the possibility of Fc-mediated ef-
fect not related to its cognate Fab domain (Figure S1C). A similarc.
trend was observed when these constructs were tested in the
B16 melanoma model in a combinatory treatment with granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) gene-
transfected B16 tumor cell vaccine (GVAX) (Figure 1B). Because
similar results were obtained in both tumor models, for consis-
tency in the following experiments we used anti-PD-1/-L1 as
monotherapies in the MC38 tumor model unless otherwise
noted. The enhanced activity of IgG2a compared to the IgG1
and IgG1-D265A subclasses of this Ab indicated that engage-
ment of activating FcgRs by this anti-PD-L1 Ab is required for
its optimal anti-tumor activity.
In contrast, a different trend was observed when we evalu-
ated the anti-tumor activity of chimeric anti-PD-1 Abs with
the different mouse Fc domains described above. The IgG1-
D265A Fc variant of the two different chimeric anti-PD-1 Ab
exhibited superior efficacy for the treatment of MC38 tumors
(Figures 1C and 1D). The optimal activity of anti-PD-1 chimeric
antibodies with an IgG1-D265A Fc indicated that FcgR engage-
ment was not required for the optimal activity of anti-PD-1 Abs.
Furthermore, when FcgR-binding capabilities were introduced
into these chimeric anti-PD-1 Abs we observed reduced anti-
tumor activity. Although both of the anti-PD-1 mAbs that we
tested had greater activity in the absence of FcgRs engage-
ment, these chimeric mAbs were distinguished by the specific
FcgR pathways that interfered with their optimal activity. The
IgG2a Fc subclass of chimeric anti-PD-1 clone 4H2 did not
result in significant anti-tumor responses, as compared to the
activity seen for this antibody when delivered as a chimera
with either mouse IgG1 or IgG1-D265A, indicating that the
reduced potency of this Ab clone resulted from the engage-
ment of activating FcgRs (Figure 1C). However, another rat
anti-PD-1 Ab clone, RMP1-14, which recognizes an epitope
distinct from 4H2 (Figure S1D), exhibited diminished activity
when administered as a chimeric antibody with either an
IgG2a or IgG1 Fc (Figure 1D). Thus, distinct FcgR-dependent
mechanisms (e.g., engagement of activating- versus inhibitory
FcgRs) may account for reduced anti-tumor activity of anti-
PD-1 Abs. Collectively, our data indicate that although
anti-PD-1 and -PD-L1 Abs were rationally designed to block
the PD-1/PD-L1 axis, distinct FcgR requirements contribute
to their activity, and therefore differentiate their in vivo mecha-
nisms of action.
Engagement of Activating FcgRs Enhances the Anti-
tumor Activity of an Anti-PD-L1 Antibody and Correlates
with Modulation of Myeloid Cell Subsets
To characterize the mechanistic basis for the activating FcgR
requirement for the anti-tumor activity of anti-PD-L1 Ab, we
compared the activity of an anti-PD-L1 antibody Ab (clone
10F.9G2) in wild-type and mice that lack all activating FcgRs
but retain the expression of inhibitory FcgRIIb (Fcer1g/)
(Clynes et al., 1998; Takai et al., 1994). 10F.9G2 is a rat IgG2b
isotype that interacts with all mouse FcgRs and has a relatively
high A/I ratio of 40 (Figure 2A). Treatment of MC38 tumors with
the 10F.9G2 anti-PD-L1 rat IgG2b clone as a monotherapy
significantly reduced the tumor volume in wild-type mice. How-
ever, this therapeutic effect was attenuated in Fcer1g/ mice
(Figure 2B). Similarly, a dependency on activating FcgR engage-
ment for anti-tumor activity of this anti-PD-L1 clone was alsoCanobserved in the B16 melanoma models (Figure S2A). Thus,
blocking of the PD-1/PD-L1 interaction by anti-PD-L1 clone
10F.9G2 was not sufficient to induce its anti-tumor therapeutic
activity. Instead, an activating FcgR-dependent mechanism
was required for optimal in vivo activity, confirming the observa-
tions in Figure 1A.
To determine if the levels of PD-L1 expression in different
splenic and tumor-infiltrating myeloid populations from mice
bearing MC38 tumors could account for this activating FcgR
requirement, we characterized myeloid cells in the TME for
PD-L1 expression. CD11b+F4/80+, CD11b+Gr-1+, and CD11b+
CD11c+ exhibited elevated PD-L1 expression levels in the
TME, as compared to the spleen (Figure 2C). PD-L1 expression
was slightly increased on the MC38 tumor cells, but at signifi-
cantly lower levels when compared to the infiltrating immune
cells. These differences in PD-L1 density could result in selective
depletion of TME myeloid cells. We evaluated the effect of anti-
PD-L1 clone 10F.9G2 on the percentages of these myeloid pop-
ulations in MC38-treated mice (Figure 2D). Anti-PD-L1 treatment
of wild-type mice resulted in the overall reduction in the percent-
ages of tumor-infiltrating CD11b+ cells, with significant reduction
observed for CD11b+F4/80+, CD11b+Gr-1+, and CD11b+
CD11c+ cells. The decrease of CD11b+Gr-1+ cells is attributed
to myeloid derived suppressor cells (MDSC) and not neutrophils
(CD11b+Ly6G+Ly6CintMHC IIF4/80), whose presence was not
affected by the treatment (Figure S2B). In contrast, CD8+ TILs
percentages were increased (Figure S2B). This decrease in the
myeloid cell populations was lost in FcgRanull mice only for
CD11b+F4/80+, but not for the other populations tested, indi-
cating that both FcgR-dependent and independent mechanisms
are responsible for reduction of TME myeloid populations. In
contrast, there was no change observed in the different myeloid
cell populations in the spleen from these anti-PD-L1 treated
tumor-bearing mice. To determine whether activating FcgR
engagement by the anti-PD-L1 antibody is responsible for the
attenuation of CD11b+F4/80+, we compared the percentages
of these cells within the overall infiltrated immune cells after
treatment of MC38 tumor-bearing mice with anti-PD-L1
10F.9G2 in wild-type and Fcer1g/ mice (Figure 2E). The
reduced percentages of CD11b+F4/80+ observed in wild-type
mice was abrogated in Fcer1g/, indicating a role for activating
FcgRs in mediating the depletion of these immunosuppressive
cells and thereby contributing to the enhanced anti-tumor activ-
ity observed for this anti-PD-L1 antibody when it engages acti-
vating FcgRs. Of clinical importance, the increase in CD3+ TILs
observed after anti-PD-L1 treatment is not affected by engage-
ment of activating FcgRs (Figure S2C).
We compared the effect of IgG2a and IgG1-D265A subclasses
for another anti-PD-L1 Ab clone, 14D8, on the overall percent-
ages and absolute numbers of myeloid and lymphocyte subpop-
ulations in the TME. Treatment with the IgG2a subclass of 14D8
Ab decreases the percentages (Figure 2F) and absolute number
(Figure S2D) of monocytes, but increases the presence of imma-
ture myeloid cells. These changes were not observed in the TME
of mice treated with the Fc null (D265A mutant) subclass. Other
myeloid cells including macrophages, dendritic cells, and neu-
trophils were not altered by either subclass (Figures 2F and
S2D). An increase of CD8 TILs is observed at similar levels after
treatment with both subclasses (Figure S2E), indicating that thecer Cell 28, 285–295, September 14, 2015 ª2015 Elsevier Inc. 287
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Figure 2. Activating FcgR Engagement Enhances Anti-PD-L1 Activity through Alternation of Myeloid Subset Percentages
(A) Relative mouse FcgR-binding profile for rat IgG2b. Binding affinities based on SPR analysis. A/I were calculated as the ratios of KD values of FcgRIV and
FcgRIIB.
(B) Wild-type and Fcer1g/mice with established MC38 tumors were treated with rat IgG2a anti-PD-L1 clone 10F.9G2 or isotype control. Data are represented
as mean ± SEM (n = 6). One of two experiments is shown.
(C) PD-L1 expression pattern of the indicated cell populations from spleens and tumors from MC38-bearing mice. Representative data from two experiments
conducted with five mice.
(D) Wild-type and FcgRanull mice with established MC38 tumors were treated with anti-PD-L1 clone 10F.9G2 or isotype control. Data are represented as mean ±
SEM of two experiments that were pooled (n > 10).
(E) Tumors from mice with genotypes and treatments as described in (B) were harvested and analyzed for the percentages of CD11b+F4/80+ cells. Dots are
individual mice. Bars represent mean ± SEM.
(F) Mice with established MC38 tumors were treated with the indicated chimeric versions of anti-PD-L1 clone 14D8 or mIgG1 isotype control. Tumors were
harvested and analyzed for the percentages of monocytes (CD11b+MHCII+/Ly6C+F4/80CD11c), macrophages (CD11b+MHC II+F4/80+CD11c+/
Ly6CLy6G), and immature myeloid cells (CD11b+MHC IIF4/80+Ly6CLy6G) cells. Dots are individual mice. Bars represent mean ± SEM.
See also Figure S2.therapeutic increase in CD8 TILs is mediated by the Fab domain
and is not affected by the Fc domain of 14D8 Ab. However, when
activating FcgRs are engaged by this Ab, distinct mechanisms
lead to modulation of the myeloid cell composition in the TME.
The combination of both FcgR engagement and PD-1/PD-L1
blocking by PD-L1 Abs thus results in optimized treatment
efficacy.288 Cancer Cell 28, 285–295, September 14, 2015 ª2015 Elsevier InActivating FcgR Engagement Results in Diminished
Anti-tumor Response for Anti-PD-1 Abs
In contrast to the results shown above for an anti-PD-L1 Ab, anti-
PD-1 Abs demonstrated reduced anti-tumor activity when their
Fc domain was able to engage FcgRs. To characterize the
involvement of FcgRs in the diminished activity of the chimeric
anti-PD-1 IgG2a Fc (clone 4H2), we compared the activity ofc.
AD
B C
Figure 3. Activating FcgRs Reduce the Efficacy of an Anti-PD-1 Antibody by Eliminating CD8 TILs
(A) Wild-type, Fcgr2b/, and Fcer1g/mice with established MC38 tumors were treated with IgG2a isotype of anti-PD-1 clone 4H2 or isotype control. Data are
represented as mean ± SEM (n = 10).
(B) Wild-type, Fcgr1/, and Fcer1g/mice with established MC38 tumors were treated with IgG2a isotype of anti-PD-1 clone 4H2 or isotype control. Data are
represented as mean ± SEM (n = 5). One of two experiments is shown.
(C) PD-1 expression of CD8+ T cell, CD4+Foxp3 (Teff), and CD4+Foxp3+ (Treg) from spleens and tumors harvested from MC38-bearing mice. Representative
data from at least two experiments conducted with five mice.
(D) Tumors and spleens of mice with the genotypes and treatments as described in (B) were harvested for single cell suspensions and analyzed for the per-
centages of the indicated cell populations. Dots are individual mice. Bars represent mean ± SEM. One of two experiments is shown.
See also Figure S3.this chimeric antibody in wild-type mice, mice that lack all acti-
vating FcgRs (Fcer1g/), and mice deficient in the inhibitory
FcgRIIb (Fcgr2b/) (Figure 3A). No significant difference in
anti-tumor activity was observed in wild-type or Fcgr2b/.
Both strains displayed only amoderate reduction i n themean tu-
mor volume when compared to mice treated with isotype control
Ab. However, significantly higher reduction in tumor volume was
observed in Fcer1g/mice, indicating the dominant role of acti-
vating FcgRs for the diminished activity of 4H2 anti-PD-1 IgG2a.
This is consistent with the preferential binding of this mouse Fc
subclass to activating FcgRs and its reduced anti-tumor activity
compared to Fc subclass with reduced or absence FcgR binding
described above. This role of FcgRs was further supported by
evaluating the activity of chimeric 4H2 anti-PD-1 IgG2a subclassCanin FcgRanull mice lacking mouse FcgR a chain-encoding genes
(Fcgr1, Fcgr2b, Fcgr3, and Fcgr4) (Smith et al., 2012); significant
anti-tumor response of this chimeric antibody was observed in
these mice, similar to that seen Fcer1g/ mice (Figure S3A).
The mouse IgG2a subclass binds to the activating Fc receptors
FcgRI, III, and IV.Wesought todetermine thecontributionof these
different activating FcgRs to the diminished anti-tumor response.
Similar to Fcer1g/mice, improved activity of the chimeric anti-
PD-1 IgG2a Fc antibody was observed in Fcgr1/ mice (Fig-
ure 3B). This effect was unique to Fcgr1/ mice and was not
observed in mice with deficiency in other activating FcgRs-,
Fcgr3/, or Fcgr4/ (Figure S3B), indicating that FcgRI is
necessary and sufficient for the reduced efficacy of anti-PD-1
treatment of this chimeric anti-PD-1 Ab/Fc configuration.cer Cell 28, 285–295, September 14, 2015 ª2015 Elsevier Inc. 289
Engagement of Activating FcgRs by Anti-PD-1
Eliminates Activated Intratumoral CD8 T Cells
The involvement of the activating FcgRI in the decreased effi-
cacy of the chimeric 4H2 anti-PD-1 IgG2a Fc Ab suggested
that ADCC-mediated depletion of PD-1-expressing cell popula-
tions by this Ab correlated with its diminished anti-tumor activity.
To identify potential targets for ADCC we determined PD-1
expression levels on T cell subsets in the TME and the periphery
(Figure 3C). PD-1 expression levels on both effector CD8+ and
CD4+Foxp3 T cells and regulatory CD4+Foxp3+ T cells were
relatively low in the spleen but upregulated within the TME.
CD8+ and CD4+ effector TILs were found to have greater PD-1
expression than intratumoral regulatory T cells. Within the
effector subsets in the TME, CD8+ cells tended to have higher
levels of surface PD-1 as compared to effector CD4+ and have
a higher percentage of PD-1+ cells. Similar PD-1 expression pat-
terns were observed in the B16 melanoma microenvironment
(data not shown).
Because PD-1 is highly expressed on CD8 TILs and anti-PD-1
treatment is correlated with increased T-cell-mediated anti-
tumor responses, we sought to determine whether CD8 TILs
are targeted through an ADCC mechanism by anti-PD-1 Ab,
thereby contributing to its reduced efficacy. First, we tested
how the presence of CD8+ TILs was affected by treatment with
the different anti-PD-1 mouse IgG subclasses (Figure S3C).
The relative percentages of CD8+ TILs were found to be corre-
lated with the binding affinities to activating FcgRs by the anti-
PD-1 mouse IgG subclass used for treatment. 4H2 anti-PD-1
IgG1 and IgG1-D265A treatments resulted in a therapeutic in-
crease of CD8+ TILs, whereas the IgG2a treated group exhibited
a significant reduction of these cells. Alternation in CD8 T cell
percentages was specific to the tumor site and did not occur
in splenic T cells, consistent with their lower PD-1 expression.
Moreover, when we tested the effect of the anti-PD-1 mouse
Fc subclasses on the relative proportion of the PD-1 expressing
CD8+ TILswe observed direct correlation between the A/I ratio of
the IgG subclass and the percentages of PD-1-positive target
CD8 TILs (Figure S3D). Because PD-1 is upregulated by acti-
vated T lymphocytes, we observed similar correlation between
the IgG A/I ratio and the percentages of activated CD8 TILs (Fig-
ure S3E). Thus, FcgR mediates the elimination of intratumoral
activated CD8+PD-1+ by anti-PD-1 IgGs. Such increased elimi-
nation of target cells by IgG2a was consistent with previous ob-
servations in a variety of in vivo experimental systems (Bulliard
et al., 2013; Clynes et al., 1998; Selby et al., 2013; Simpson
et al., 2013).
Wewished to elucidate the contribution of activating FcgRs for
the attenuation in intratumoral T cell populations. Because of the
improved activity of 4H2 anti-PD-1 IgG2a in Fcer1g/ and
Fcgr1/ mice we evaluated the effect of anti-PD-1 treatment
on different T cell subsets in these mice (Figure 3D). While the
chimeric 4H2 anti-PD-1 IgG2a Fc antibody resulted in 48%
reduction in the percentages of CD8+ TILs in wild-type mice,
their relative presence within the overall immune cells in the
TME after treatment was increased by 4.5- and 2.6-fold in
Fcer1g/ and Fcgr1/ mice, respectively. This confirmed a
role for activating FcgRs in anti-PD-1-mediated CD8+ elimination
from the tumor site, and therefore in the abrogation of their acti-
vation and proliferation needed for effective immunotherapy. The290 Cancer Cell 28, 285–295, September 14, 2015 ª2015 Elsevier Ineffect of activating FcgRswas specific to intratumoral CD8+ cells
since the percentages of effector and regulatory CD4 T cells
were not altered by this chimeric anti-PD-1 antibody. Although
a slight reduction in the percentages of effector CD4 T cells
was observed in tumors from Fcer1g/ and Fcgr1/ mice
compared to untreated mice, this trend was not statistically sig-
nificant when compared to anti-PD-1 treated wild-type mice or
when total numbers of CD4 T cells per tumor mass were evalu-
ated (Figure S3F). No changes in the splenic T cells subset pop-
ulations were observed after anti-PD-1 treatment. Thus, the
elevated PD-1 expression levels on CD8+ TILs were consistent
with the CD8+-specific elimination observed by 4H2 anti-PD-1-
IgG2a in the TME. Collectively, our data support the conclusion
that in the absence of FcgR engagement, anti-PD-1 treatment
leads to increased CD8+ T cell percentages within the TME,
presumably by blocking their PD-1 inhibitory signal. FcgR
engagement by anti-PD-1 targets CD8 TILs by ADCC and there-
fore reduces their percentages. This decrease of CD8+ TILs
correlates with the poor anti-tumor activity induced by 4H2
anti-PD-1 IgG2a.
Decreased Efficacy of Anti-PD-1 Treatment by
Engagement of FcgRIIb
In contrast to the chimeric anti-PD-1 antibody derived from clone
4H2 with a mouse IgG1 Fc, the chimeric anti-PD-1 clone RMP1-
14 with a mouse IgG1 Fc had significantly diminished anti-tumor
activity (Figure 1), implying that engagement of the FcgRIIB
pathway may limit the optimal activity of this Ab clone. The
anti-PD-1 Ab produced by the hybridoma clone RMP1-14 is a
rat IgG2a subclass (Yamazaki et al., 2005), and had shown
anti-tumor activity in the treatment of variety murine tumor
models (Curran et al., 2010; Lu et al., 2014; Peng et al., 2012).
ELISA- (Figure S4A) and surface plasmon resonance (SPR)- (Fig-
ure 4A) based analysis of the rat IgG2a binding profile to mouse
FcgRs revealed that this subclass bound only the low-affinity
mouse FcgRIIb and FcgRIII with KD of 6.1 3 10
6 and 2.3 3
105, respectively. (In contrast, the mouse IgG2a subclass binds
mouse high-affinity FcgRI and IV preferentially). We therefore
assessed the anti-tumor activity of this rat antibody in wild-
type, Fcgr2b/, and Fcgr3/ mice. Although treatment of
wild-type mice with rat anti-PD-1 RMP1-14 clone (rat IgG2a)
resulted in reduction inMC38 tumor volume, significant improve-
ment in the anti-tumor response was achieved in Fcgr2b/
mice (Figure 4B). In contrast, FcgRIII deficiency did not affect
the therapeutic efficacy of this rat anti-PD-1 clone (Figure S4B),
implying FcgRIIb-mediated diminished efficacy of RMP1-14
anti-PD-1. This is consistent with the diminished activity
observed for chimeric RMP1-14 anti-PD-1 mouse IgG1 Fc,
which preferentially engages FcgRIIB, compared to the Fc null
IgG1-D265A subclass. Next, we analyzed the effect of FcgRIIb
engagement on the expansion of intratumoral CD8 T cells
during RMP1-14 anti-PD-1 treatment (Figure 4C). The enhanced
effect of RMP1-14 anti-PD-1 (rat IgG2a) treatment in Fcgr2b/
resulted in complete tumor rejection in 60% of the treated
mice (compared to 0% in wild-type mice) at day 7 after treat-
ment onset. We therefore analyzed tumors from mice at earlier
time points than in the previous experiments and prior to
the completion of our Ab treatment protocol. Similar percent-
ages of CD8 TILs were observed in tumors from control andc.
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Figure 4. FcgRIIb Engagement Reduces the Efficacy of Anti-PD-1 Treatment
(A) Relative FcgR-binding profile for various rat and human IgG Fc variants. Binding affinities based on SPR analysis. A/I were calculated as the ratios of KD values
of FcgRIII (mouse) or FcgRIIIAF158 (human) and FcgRIIB.
(B) Wild-type and Fcgr2b/mice with established MC38 tumors were treated with anti-PD-1 clone RMP1-14 or isotype control. Data are represented as mean ±
SEM (n > 8).
(C) Wild-type and Fcgr2b/ with established MC38 were injected two or three times with RMP1-14 and tumors were harvested at days 4 or 7 post-treatment
onset, respectively. Dots are individual mice. Bars represent mean ± SEM.
(D) Humanized FcgRs mice with established MC38 tumors were treated with human IgG1-N297A or IgG4 subclasses of anti PD-1 clone RMP1-14. Data are
represented as mean ± SEM. One of three experiments is shown (n = 11).
See also Figure S4.RMP1-14 anti-PD-1 (rat IgG2a)-treated wild-type mice at day 4
(after two Ab injections), while in Fcgr2b/ mice CD8+ TILs
were increased by 2-fold compared to wild-type mice. FcgRIIb
tended to delay, but not to prevent, the expansion of CD8 TILs
because after completion of the Ab treatment (day 7), there
was a significant increase in their percentages in treated wild-
type mice as well.
Several humanized anti-PD-1 Abs, including nivolumab and
pembrolizumab, both recently approved by the FDA, are of the
human IgG4 subclass, a subclass that has relatively low binding
affinities to human FcgRs. Rationally designed as blocking re-
agents, these Abs were developed as human IgG4 to avoid Fc-
mediated cytotoxic effects on T cells. Compared to human
IgG1 and IgG3, IgG4 had significantly reduced binding affinity
to human activating FcgRs, but retain binding to the human
inhibitory FcgRIIb receptor, resulting in a relative low A/I ratio
of 1 (Bruhns et al., 2009) (Figure 4A). We therefore sought to
test whether administration of a chimeric rat anti-PD-1 RMP1-
14 clone with a human IgG4 Fc would alter its activity compared
to the chimeric antibody with the FcgR null binding human IgG1-CanN297A Fc. We generated two human IgG Fc variants of the rat
anti-mouse PD-1 clone RMP1-14: either with a human IgG4 Fc
immunoglobulin with a stabilizing S228P mutation (Lewis et al.,
2009) or with the human IgG1-N297A FcgR null binding variant
(Figure 4A). Because murine systems are not suitable to study
human IgG Fc effector functions in vivo, we used amousemodel
we developed recently in which the mouse FcgRs had been
deleted and all the human FcgRswere expressed as transgenes,
faithfully recapitulating the human-specific FcgR expression
pattern and diversity (Smith et al., 2012). We compared the
anti-tumor response of these two chimeric versions of anti-
PD-1 clone RMP1-14 with human Fc in humanized FcgRs mice
bearing MC38 tumors (Figure 4D). Treatments with both chi-
meras of anti-PD-1 RMP1-14 clone, containing human IgG1-
N297A or IgG4 Fcs, resulted in a similar significant tumor growth
inhibition and in a total of 70% (16 of 23) and 63% (15 of 24)
tumor-free mice, respectively. Thus, in contrast to our observa-
tion for themouse IgG1 Fc subclass, adding FcgR-binding capa-
bilities in the form of human IgG4 Fc does not alter the anti-tumor
activity of this anti-PD-1 clone.cer Cell 28, 285–295, September 14, 2015 ª2015 Elsevier Inc. 291
DISCUSSION
The emergence of immunomodulatory antibodies for the treat-
ment of neoplastic diseases is a milestone in therapeutic ap-
proaches to cancer. It has become apparent, however, that the
in vivo activity of these antibodies result from both Fab- and
Fc-mediated pathways (Bulliard et al., 2014; Li and Ravetch,
2011; White et al., 2011). We now report on the evaluation of
the role of Fc-FcgR interactions in the activity of the Abs target-
ing the PD-1 immune checkpoint pathway. Optimal anti-tumor
activity of Abs targeting PD-1 was achieved by blocking of the
inhibitory PD-1 signal in the absence of Fc-FcgR engagement;
FcgR engagement by anti-PD-1 Abs resulted in diminished
in vivo activity. Although this negative effect of FcgR engage-
ment was observed for two distinct antibodies recognizing
distinct epitopes on PD-1, the mechanism by which FcgR
engagement resulted in reduced efficacy differed. The 4H2
anti-PD-1 antibody engagement of activating FcgR resulted in
the elimination of effector CD8+ in the TME by ADCC. However,
for another anti-PD-1 Ab recognizing a different epitope on PD-1
(clone RMP1-14), engagement of the inhibitory FcgR resulted in
diminished in vivo anti-tumor activity, implicating that epitope-
specific mechanisms governed the impact of FcgR engagement
by this class of immune checkpoint Abs. In contrast to anti-PD-1
Abs, blocking of this axis by disrupting anti-PD-L1 binding by
anti-PD-L1 was enhanced by engagement of activating FcgRs.
This effect was correlated to elimination of monocytes and mod-
ulation of myeloid cells within the TME by anti-PD-L1.
We identified FcgRI as the Fc receptor that was responsible for
triggering the elimination of CD8 TILs by the anti-PD-1/IgG2a.
This dependence on FcgRI was unexpected considering previ-
ous observations in multiple experimental settings, indicating
that although FcgRI is capable of binding IgG2awith high affinity,
it does not contribute to the in vivo activity of this subclass of
IgGs, presumably as a consequence of the saturation of the re-
ceptor by circulating IgG. FcgRIV, an intermediate affinity acti-
vating FcgR, is the primary activating FcgR that mediates
ADCC by the IgG2a subclass (DiLillo and Ravetch, 2015; Hama-
guchi et al., 2006; Nimmerjahn et al., 2010). For example, in the
B16 melanoma model, direct killing of tumor cells by the anti-
gp75 Ab TA99 and elimination of intratumoral Tregs by anti-
CTLA4 were mediated through FcgRIV (Nimmerjahn et al.,
2010; Simpson et al., 2013). Similar observations had been
made in a variety of solid and liquid tumor models, supporting
the conclusion that FcgRI, by virtue of its nanomolar affinity for
IgG2a, insures its saturation by normal serum concentrations
of IgG2a and is unavailable to be recruited by therapeutic Abs.
The finding that in the MC38 tumor model mouse FcgRI was
responsible for depletion of CD8 effector cells by an IgG2a sub-
class Fc suggests that the TME may modulate FcgRs differen-
tially than observed on circulating or tissue macrophages.
Two distinct FcgR-mediated mechanisms were recently
described for enhancing the potency of immunomodulatory
Abs: the engagement of activating FcgR for ADCC-mediated
depletion of intratumoral regulatory lymphocytes that overex-
press the target antigen (e.g., CTLA-4, OX-40, and GITR), or
the engagement of the inhibitory FcgRIIb to provide a scaffold
for Ab cross-linking, and therefore enhance the agonistic activity
of Abs targeting TNFR family members such as anti-CD40 and292 Cancer Cell 28, 285–295, September 14, 2015 ª2015 Elsevier InDR5. We observed that anti-PD-1 Abs may engage either of
these two distinct FcgR-dependent mechanisms to reduce the
potency of this class of antibodies, depending on both their Fc
and Fab domains. When engaged, both pathways diminished
the therapeutic potential of these immunomodulatory Abs.
Thus, for the anti-PD-1 clone, RMP1-14, engagement of both
activating (when administered as IgG2a) and inhibitory FcgRs
(when administered as IgG1) resulted in reduced activity when
compared to an FcgR null variant. The reduced activity upon
engagement of activating FcgR was shared by the other anti-
PD-1 clone tested. However, the FcgRIIb pathway was unique
to this clone. We speculate that FcgRIIb engagement by clone
RMP1-14 may contribute partial agonistic activity to this clone
and therefore deliver augmented inhibitory PD-1 signals that
may interfere with its therapeutic PD-1 blocking activity. Alterna-
tively, engagement of FcgRIIb may directly influence FcgRIIb-
expressing cells in the tumor microenvironment by altering their
activation state and phenotype, thus suppressing T cells in a
PD-1 independent manner. Studies elucidating the mechanistic
basis for the FcgRIIb-mediated reduced efficacy by anti-PD-1
are undergoing.
CTLA-4 and PD-1 are the only targets for immune checkpoint
blocking Abs approved to date by the FDA for the treatment of
cancer. The observation that anti-CTLA-4 Abs mediate their
anti-tumor activity, in part, through depletion of intratumoral
Tregs (Bulliard et al., 2013; Romano et al., 2014; Selby et al.,
2013; Simpson et al., 2013) highlights the potential role of FcgRs
in the activity of immune checkpoint blocking Abs. However, we
observed that not only are anti-PD-1 Abs FcgR independent but
also that FcgRs engagement reduced their therapeutic potency.
Whereas Abs targeting both CTLA-4 and PD-1 aim to mediate
therapeutic increases in the intratumoral Teff/Treg ratio, the
distinct expression pattern of these immune receptors distin-
guishes the FcgR requirement and in vivo mechanism of
these blocking Abs. CTLA-4 expression density is higher on
the regulatory TIL compartment, whereas PD-1 is relatively over-
expressed on effector TILs. Therefore, preferential depletion of
regulatory versus effector T cells by anti-CTLA-4 or PD-1,
respectively, results in correspondingly enhanced or diminished
Teff/Treg ratios. With the understanding that many of the immu-
nomodulatory Abs now being tested as therapies will mediate
their in vivo effects through different mechanisms depending
on their target molecule, target cell, and TME, each class of
immunomodulatory Abs will need to be individually analyzed to
determine their in vivo FcgR requirements based on their mech-
anisms of action.
In contrast to the FcgR-independentmechanisms of anti-PD-1
Abs, an anti-PD-L1 Ab displayed significantly enhanced anti-tu-
mor activity only when activating FcgR engagement was opti-
mized. This enhanced activity was correlated with diminished
F4/80-positive cells in the MC38 tumor model. The therapeutic
potential of targeting TAMs has been demonstrated for a variety
of tumors (Fritz et al., 2014; Noy and Pollard, 2014). In many tu-
mor types, TAMs are polarized to a tumor-promoting phenotype,
and stimulate tumor initiation and progression, including angio-
genesis, tumor invasion, motility, and metastasis (Qian and
Pollard, 2010). In addition, these TAMs are immunoregulatory
and suppress the T cell-mediated anti-tumor immune response
in the TME (Coussens et al., 2013). Direct targeting of PD-L1c.
expressing myeloid cells may account for the enhanced activity
of anti-PD-L1 Abs upon engagement of activating FcgRs. This
pathway seems to synergize with the FcgR-independent block-
ing activity of ant-PD-L1 thereby augmenting the anti-tumor
activity of effector T cells.
Whereas the proportion of different myeloid cell populations
are reduced in a similar degree after anti-PD-L1 10F.9G2 clone
treatment, we observed that only F4/80-positive cells reduction
is FcgR-dependent, whereas MDSC reduction is not. MDSC
reduction after anti-PD-L1 treatment has been reported previ-
ously in different tumor models (Curran et al., 2010). This atten-
uation in MDSC localization in the TME is also associated with
reduction in their suppressive phenotype (Duraiswamy et al.,
2013), and is mediated through TNF, which is secreted by
CD8+ TILs upon their stimulation by anti-PD-L1 (Deng et al.,
2014). We observed similar PD-L1 expression levels on both
F4/80-positive cells and MDSC. The basis for this differential
dependence on FcgR engagement remains to be elucidated.
Although our studies provide evidence for a role for PD-L1
expression on myeloid cells for the enhanced therapeutic effect
of anti-PD-L1 upon engagement of activating FcgRs, they do not
address the relative contribution of PD-L1 expressed by tumor
cells. The importance of PD-L1 expression by tumor cells and in-
filtrated immune cells has been recently demonstrated in clinical
settings (Tumeh et al., 2014). Indeed, PD-L1 expression by
infiltrating leukocytes correlates with patients’ response to
anti-PD-L1 treatment (Herbst et al., 2014). Further clinical
studies elucidating the contribution of PD-L1 on tumor cells,
tumor stroma, and the different infiltrating leukocytes are war-
ranted to highlight potential predictive markers for anti-PD-1/
PD-L1 treatments.
This study has significant implications for the selection of the
optimal Fc for anti-PD-1/PD-L1 Abs. Both anti-PD-1 mAbs
approved for the treatment of advanced melanoma, nivolumab
(Topalian et al., 2012) and pembrolizumab (Hamid et al., 2013),
are human IgG4 isotypes. This isotype was selected due to the
low affinity binding of IgG4 to human FcgRs to avoid ADCC-
mediated depletion of PD-1 expressing cells. We have shown
that, depending on the epitope recognized, inhibitory FcgRIIB
engagementmay diminish the activity of anti-PD-1 Abs. By using
mice humanized for FcgRs, we have demonstrated that IgG4
isotype of an anti-PD-1 Ab may not alter the anti-tumor activity
compared to FcgR null mutant. However, the reduced activity
of mouse IgG1 through interaction with FcgRIIB suggest that in-
teractions with FcgRIIB should also take into consideration when
selecting human IgG Fc scaffolds for anti-PD-1 Abs. Pidilizumab
is a humanized IgG1 anti-PD-1 mAb in clinical development.
Based on the relatively high-affinity interaction of IgG1 with acti-
vating FcgRs and our preclinical studies that demonstrate FcgR-
mediated depletion of intratumoral Teff, this Ab may result with
unwanted depletion of effector TILs and therefore display
reduced anti-tumor activity. Therefore an FcgR null IgG variant
of anti-PD-1 is predicted to be the optimal candidate for thera-
peutic blocking of PD-1 by avoiding the unwanted engagement
of FcgR pathways.
Four different Abs targeting PD-L1 are currently being investi-
gated in clinical trials: BMS-936559 (IgG4), MPDL3280A and
MEDI4736 (IgG1s engineered to eliminate Fc-FcgR interactions),
and MSB0010718C (IgG1). The variety of IgG isotypes with dif-Canferential FcgR-binding properties developed by the different
companies can provide valuable insight into the contribution of
FcgRs for anti-PD-L1 treatment of human malignancies. Further
evaluation of the effector cells expressing FcgRs in different hu-
man tumor types, PD-L1 expression levels by different myeloid
cells, and the efficacy of the different anti-PD-L1 isotypes should
provide valuable information regarding the involvement of FcgR
pathways in the activity of anti-PD-L1 Ab treatment in cancer
patients, andmay provide rational for the design of IgG construct
for optimal clinical anti-tumor activity.
EXPERIMENTAL PROCEDURES
A detailed description of the experimental procedures is provided in the Sup-
plemental Experimental Procedures.
Mice
Mice 7–10 weeks of age were used in all experiments.
All mice were maintained in The Rockefeller University Comparative Biosci-
ence Center. All experiments were performed in compliance with federal laws
and institutional guidelines and had been approved by The Rockefeller Univer-
sity IACUC.
Tumor Challenge and Treatment
MC38 cells (23 106) were implanted subcutaneously (s.c), and tumor volumes
were measured every 2–3 days with an electronic caliper and reported as vol-
ume using the formula (L1
23 L2)/2, where L1 is the shortest diameter and L2 is
the longest diameter. Five to seven days after tumor inoculation, mice were
randomized by tumor size (day 0) and received intraperitoneal (i.p) injection
of 200 mg anti-PD-1, anti-PD-L1, or control IgG. Mice received an additional
200 mg of IgG treatment at days 3 and 6. For the B16 model, mice were chal-
lenged with 2 3 105 B16-F10 cells s.c, and after 3 days (day 0), were treated
with 106 irradiated B16-GM-CSF-secreting cells (GVAX) s.c and the first IgG
treatment i.p. Additional IgGs were injected at days 3 and 6.
Tissue Processing and Flow Cytometry
For functional experiments, mice were challenged and treated as described
above, and were killed at day 8, unless otherwise indicated. Spleens were
dissected through a 70 mm nylon cell strainer, incubated with red blood cells
lysis buffer (Sigma), and washed. Tumors were mechanically dissected and,
in most cases, incubated with DNase and Liberase TL (Roche) before
dispersed through a 70 mm nylon cell strainer. Different cell populations
were identified after excluding dead cells using live/dead fixable aqua dead
cell dye (Life Technologies). For intracellular staining, cells were fixed and per-
meabilized with Foxp3 Fix/Perm buffer kit (Bioleagend).
CountBright Absolute Counting Beads (Life Technologies) were added prior
to acquisition. Cell populations were defined by the following markers: mono-
cytes (CD11b+MHC II+/Ly6C+F4/80CD11c), macrophages (CD11b+MHC
II+F4/80+CD11c+/Ly6CLy6G), immature myeloid cells (CD11b+MHC
IIF4/80+Ly6CLy6G), neutrophils (CD11b+Ly6G+Ly6CintMHC IIF4/80),
dendritic cells (CD11b+CD11c+MHC II+F4/80), CD8 T cells (CD3+CD8+),
CD4 effector T cells (CD3+CD4+Foxp3), and CD4 regulatory T cells (CD3+
CD4+Foxp3+). Data were acquired on Fortessa flow cytometers (BD) and
analyzed using FlowJo software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccell.2015.08.004.
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